TEASER 2

GLOBAL EXPERT SUMMIT ON HYPOPARATHYROIDISM

ASSESSING AND MANAGING A COMPLEX DISEASE

Complications and comorbidities define the journey of the patient with hypoparathyroidism

Prof. John P. Bilezikian

20th–21st Nov, 2020

Code: VV-MEDMAT-2430 – Date of preparation: August 2020
This meeting is initiated, organized and funded by Takeda. This event is for healthcare professionals only.
Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).

TEASER 2

Complications and comorbidities define the journey of the patient with hypoparathyroidism

Transcript

Hello and Welcome!

My name is **John P. Bilezikian**.

I'm an endocrinologist from Columbia University in New York and I would like to briefly preview the exciting work we will discuss on November 20th during the second session of this year's virtual Global Expert Summit on Hypoparathyroidism (GESH).

Notes/slides

John P. Bilezikian

Professor of Medicine and Professor of Pharmacology
Vagelos College of Physicians & Surgeons
Vice-chair of the Department of Medicine for International Research and Education
Columbia University
New York, USA

TEASER 2

Complications and comorbidities define the journey of the patient with hypoparathyroidism

Transcript

As we all know, the loss of parathyroid hormone and associated impaired mineral homeostasis affects many organ systems in patients with hypoparathyroidism.

Notes/slides



* These manifestations are mostly the result of treatment with calcium and activated vitamin D rather than of the disorder itself

Mannstadt M, et al. *Nat Rev Dis Primers*. 2017;3:17055.

TEASER 2

Complications and comorbidities define the journey of the patient with hypoparathyroidism

Transcript

Hypocalcemia secondary to hypoparathyroidism can result in cardiomyopathy.

Notes/slides



Magnetic resonance image showing left ventricular hypertrophy

Hoey ET, et al. *Quant Imaging Med Surg*. 2014;4(5):397-406.

TEASER 2

Complications and comorbidities define the journey of the patient with hypoparathyroidism

Transcript

Hypoparathyroidism and conventional treatment also lead to arterial calcification and arterial stiffness, which are associated with increased risk for cardiovascular disease.

Notes/slides



Axial computed tomography images show eccentric calcified plaques in proximal right coronary and left anterior descending artery

Text: Agarwal P, et al. *Indian J Endocrinol Metab*. 2015;19(6):785-790.
Underbjerg L, et al. *Clin Endocrinol (Oxf)*. 2019;90(4):592-600.
Pamuk N, et al. *Arch Endocrinol Metab*. 2020;S2359-39972020005002216.
Image: Agarwal P, et al. *Indian J Endocrinol Metab*. 2015;19(6):785-790.

TEASER 2

Complications and comorbidities define the journey of the patient with hypoparathyroidism

Transcript

Patients with hypoparathyroidism may have calcification in the brain.

Notes/slides



Computed tomography of the brain showed multiple calcifications in the dentate nucleus and basal ganglia

Image: Zhou YY, et al. *World J Clin Cases*. 2019;7(21):3662-3670.

TEASER 2

Complications and comorbidities define the journey of the patient with hypoparathyroidism

Transcript

Conventional treatment of hypoparathyroidism also has the potential to result in nephrocalcinosis and the development of renal stones.

Notes/slides

An X-ray showing nephrocalcinosis

Text: Mannstadt M, et al. *Nat Rev Dis Primers*. 2017;3:17055.
Image: http://www.learningradiology.com/archives2013/COW%20546-Medullary%20Nephrocalcinosis/mednephrocorrect.html, accessed Aug 2020.

TEASER 2

Complications and comorbidities define the journey of the patient with hypoparathyroidism

Transcript (This will be ANIMATED)

The second session of this year Global Expert Summit on Hypoparathyroidism will consider the wide range of complications and comorbidities observed in patients with hypoparathyroidism and the complex journey that they face over the course of their disease.

Prof. Andrea Giustina will consider the complex interplay of different hormones – parathyroid hormone and vitamin D, the renin-angiotensin-aldosterone system, antidiuretic hormone, insulin-like growth factor-1, and fibroblast growth factor-23 in hypoparathyroid patients with chronic kidney disease.

Prof. Pascal Houillier will then review the consequences of hypercalciuria/hypercalcemia in patients being treated for hypoparathyroidism, renal disease progression in these patients, and links to calcium-containing stone formation.

Prof. Jens Bollerslev will outline cardiac manifestations of hypoparathyroidism while **Prof. Lars Rejnmark** will extend this discussion with a consideration of arterial stiffness and calcium/phosphate imbalance in these patients.

Following this, **Prof. Nicola Napoli** will summarize the latest data about impaired glucose metabolism and diabetes in hypoparathyroidism.

Prof. Leif Østergaard will review what is known regarding mechanisms underlying brain involvement in patients with hypoparathyroidism.

This session will close with a live, interactive panel discussion that will address the journey of the patient with hypoparathyroidism and how it is influenced by interactions among all of the factors considered in the presentations.

Notes/slides

P1  **Andrea Giustina**

P2  **Pascal Houillier**

P3  **Jens Bollerslev**

P4  **Lars Rejnmark**

P5  **Nicola Napoli**

P6  **Leif Østergaard**

Pnl  **Sigrídur Björnsdóttir**

Pnl  **Line Underbjerg**

TEASER 2

Complications and comorbidities define the journey of the patient with hypoparathyroidism

Transcript

We are very much looking forward to a very dynamic session during this year's virtual meeting.

Thus, Save-the-Date and interact with us on November 20th!

Notes/slides

TEASER 2

GLOBAL EXPERT SUMMIT ON HYPOPARATHYROIDISM

ASSESSING AND MANAGING A COMPLEX DISEASE

Complications and comorbidities define the journey of the patient with hypoparathyroidism

Save the date!

Code: VV-MEDMAT-2430 – Date of preparation: August 2020
This meeting is initiated, organized and funded by Takeda. This event is for healthcare professionals only.
Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).